Skip to main content

Table 2 Comparison of combined hepatocellular carcinoma and cholangiocarcinoma versus hepatocellular carcinoma or cholangiocarcinoma after propensity score matching

From: Clinical features and outcomes of combined hepatocellular carcinoma and cholangiocarcinoma versus hepatocellular carcinoma versus cholangiocarcinoma after surgical resection: a propensity score matching analysis

Variable cHCC-CC (n = 35) HCC (n = 35) p value cHCC-CC (n = 35) CC (n = 35) p value
Male 28 (80.0) 29 (82.9) 0.759 28 (80.0) 25 (71.4) 0.339
Age (years) 57 (37–79) 57 (35–81) 0.894 57 (37–79) 60 (35–80) 0.199
Smoking 7 (20.0) 13 (37.1) 0.112 7 (20.0) 4 (11.4) 0.324
Alcohol use 10 (28.6) 11 (31.4) 0.794 10 (28.6) 4 (11.4) 0.209
HBV positive 15 (42.9) 20 (57.1) 0.232 15 (42.9) 17 (48.6) 0.631
HCV positive 8 (22.9) 5 (14.3) 0.356 8 (22.9) 13 (37.1) 0.192
Total bilirubin 0.93 ± 0.32 0.85 ± 0.28 0.455 0.93 ± 0.32 0.95 ± 0.45 0.861
Albumin 4.1 ± 0.3 4.1 ± 0.3 0.481 4.1 ± 0.3 4.2 ± 0.3 0.102
INR 1.04 ± 0.04 1.06 ± 0.06 0.060 1.04 ± 0.04 1.05 ± 0.11 0.446
Cirrhosis 12 (34.3) 11 (31.4) 0.799 12 (34.3) 6 (17.1) 0.107
Child–Pugh class A 35 (100) 34 (97.1) 0.801 35 (100) 35 (100) 1.000
Edmondson–Steiner Grades, I–II 12 (34.2) 13 (37.5) 0.313 12 (34.2) 11 (31.4) 0.861
Tumor size 6.6 ± 3.5 7.4 ± 4.3 0.055 6.6 ± 3.5 6.0 ± 2.8 0.125
Tumor size ≥ 5 cm 24 (68.6) 25 (71.4) 0.794 24 (68.6) 19 (54.3) 0.220
Tumor number (≥ 2) 3 (8.6) 6 (17.1) 0.284 3 (8.6) 1 (2.9) 0.303
AFP (ng/mL) ≥ 200 8 (22.9) 13 (37.1) 0.192 8 (22.9) 3 (8.6) 0.101
ICG% 10.7 ± 5.4 9.2 ± 5.0 0.232 10.7 ± 5.4 9.3 ± 5.6 0.268
Operative margin > 1 cm 12 (34.3) 11 (31.4) 0.799 12 (34.3) 18 (51.4) 0.198
Major hepatectomy 15 (42.8) 16 (45.7) 0.783 15 (42.8) 20 (57.1) 0.328
Microvascular invasion 13 (37.5) 12 (34.2) 0.803 13 (37.5) 6 (17.1) 0.060
Macrovascular invasion 5 (14.3) 12 (34.2) 0.056 5 (14.3) 1 (1.9) 0.088
Lympho nodules metastasis 7 (20.0) 3 (8.5) 0.095 7 (20.0) 7 (20.0) 1.000
Distal metastasis 0 (0) 0 (0) 1.000 0 (0) 1 (2.9) 0.314
AJCC stage, I–II 10 (55.6) 12 (34.3) 0.137 10 (55.6) 11 (55.0) 0.973
Antiviral therapy 15 (42.8) 16 (45.7) 0.781 15 (42.8) 20 (57.1) 0.329
Recurrence 9 (25.7) 11 (31.4) 0.597 9 (25.7) 4 (11.4) 0.124
Mortality 14 (40.0) 16 (45.7) 0.629 14 (40.0) 20 (57.1) 0.151
Follow up times (months) 31 (4–75) 52 (1–98) 0.001 31 (4–75) 24 (1–85) 0.129
  1. Data are presented as the median (range) or number (percentage)
  2. HBV Hepatitis B virus, HCV hepatitis C virus, INR international normalized ratio, AFP alpha-fetoprotein, ICG indocyanine green, AJCC American Joint Committee on Cancer